LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Shunta Mori,Hiroki Izumi,Mitsugu Araki,Jie Liu,Yu Tanaka,Yosuke Kagawa,Yukari Sagae,Biao Ma,Yuta Isaka,Yoko Sasakura,Shogo Kumagai,Yuta Sakae,Kosuke Tanaka,Yuji Shibata,Hibiki Udagawa,Shingo Matsumoto,Kiyotaka Yoh,Yasushi Okuno,Koichi Goto,Susumu S. Kobayashi

DOI: https://doi.org/10.1038/s42003-024-06116-6

IF: 6.548

2024-04-05

Communications Biology

Abstract:The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusion. However, it is expected that acquired resistance will inevitably develop, particularly by LTK mutations, as observed in NSCLC induced by oncogenic tyrosine kinases treated with corresponding tyrosine kinase inhibitors (TKIs). In this study, we evaluate eight LTK mutations corresponding to ALK mutations that lead to on-target resistance to lorlatinib. All LTK mutations show resistance to lorlatinib with the L650F mutation being the highest. In vitro and in vivo analyses demonstrate that gilteritinib can overcome the L650F-mediated resistance to lorlatinib. In silico analysis suggests that introduction of the L650F mutation may attenuate lorlatinib-LTK binding. Our study provides preclinical evaluations of potential on-target resistance mutations to lorlatinib, and a novel strategy to overcome the resistance.

biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanism of lorlatinib resistance caused by the CLIP1 - LTK fusion protein in non - small - cell lung cancer (NSCLC). Specifically, the study aims to evaluate LTK mutations that may lead to resistance to lorlatinib and explore potential strategies to overcome these resistances.

### Background
- **CLIP1 - LTK fusion protein**: Recently discovered as a new oncogenic driver in non - small - cell lung cancer. This fusion protein promotes cell proliferation and inhibits apoptosis by activating LTK and its downstream signaling molecules such as AKT and ERK.
- **Lorlatinib**: A third - generation ALK inhibitor, which has shown significant clinical efficacy in NSCLC patients carrying the CLIP1 - LTK fusion protein. However, acquired resistance is expected to inevitably occur during the treatment process, especially resistance caused by LTK mutations.

### Research Objectives
1. **Evaluate LTK mutations**: The researchers evaluated eight LTK mutations corresponding to ALK mutations that may lead to resistance to lorlatinib.
2. **Verify the resistance mechanism**: Through in vitro and in vivo experiments, verify whether these LTK mutations do indeed lead to resistance to lorlatinib.
3. **Find ways to overcome resistance**: The researchers tested a variety of compounds to determine which drugs can overcome lorlatinib resistance caused by LTK mutations, especially the L650F mutation.

### Main Findings
- **LTK mutations lead to resistance**: All of the evaluated LTK mutations showed resistance to lorlatinib, with the L650F mutation having the strongest resistance.
- **Effectiveness of gilteritinib**: In vitro and in vivo experiments showed that gilteritinib can overcome lorlatinib resistance caused by the L650F mutation. Specifically, gilteritinib can effectively inhibit LTK phosphorylation of the L650F mutation and induce apoptosis.
- **Molecular dynamics simulation**: Through molecular dynamics simulation, the researchers found that the L650F mutation may weaken the binding of lorlatinib to LTK, thus explaining its resistance mechanism.

### Conclusion
This study is the first to explore the mechanism of lorlatinib resistance of the CLIP1 - LTK fusion protein in NSCLC and proposes gilteritinib as a potential strategy to overcome resistance caused by the L650F mutation. These findings provide important scientific basis for the development of more effective treatment regimens.